Peregrine Pharmaceuticals, Inc. (PPHM) halted, news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Peregrine Pharma (PPHM) Pops Higher on Resumption
May 20, 2013 9:16 AM EDTPeregrine Pharmaceuticals (Nasdaq: PPHM) pops higher on resumption. Shares are up 17 percent early.... More
Peregrine Pharma (PPHM) to resume trading at 9:15am ET
May 20, 2013 9:12 AM EDTPeregrine Pharma (Nasdaq: PPHM) to resume trading at 9:15am EDT.... More
Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
May 20, 2013 8:48 AM EDTPeregrine Pharmaceuticals (Nasdaq: PPHM) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer (NSCLC). The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. Final data from the study will be presented at the upcoming ASCO Annual Meeting on Saturday, June 1, 2013.
"We are very pleased with the outcome from this highly... More
